Table 3 Disease progression from LSIL to HSIL by HPV types

LSIL to HSIL

245

45

25.7 (18.3–32.3)

Age

 20–29

59

10

22.5 (8.4–34.3)

Ref

Ref

 30–39

71

17

30.6 (16.3–42.5)

1.30 (0.60–2.84)

1.30 (0.58–2.90)

0.520

 40–49

69

15

32.0 (15.8–45.0)

1.14 (0.51–2.53)

1.10 (0.49–2.48)

0.818

 50–59

46

3

10.5 (0.0–21.2)

0.34 (0.09–1.24)

0.39 (0.11–1.48)

0.167

HPV type at baseline

 Low-risk

104

8

10.9 (2.9–18.4)

Ref

Ref

 HPV-16

49

17

45.2 (24.8–60.0)

4.69 (2.03–10.88)

4.71 (2.02–11.02)

0.001

 HPV-18

22

4

20.9 (0.3–37.3)

2.34 (0.71–7.78)

2.72 (0.81–9.13)

0.105

 HPV-31

12

2

16.7 (0.0–35.3)

3.08 (0.65–14.53)

2.87 (0.60–13.68)

0.186

 HPV-33

14

4

68.2 (0.0–92.8)

3.96 (1.19–13.18)

4.17 (1.25–13.94)

0.021

 HPV-45

9

1

11.1 (0.0–29.4)

1.59 (0.20–12.74)

2.96 (0.36–24.64)

0.316

 HPV-52

34

7

22.2 (6.1–35.5)

2.64 (0.96–7.29)

3.42 (1.23–9.52)

0.019

 HPV-58

51

15

43.1 (22.0–58.5)

4.17 (1.77–9.84)

4.37 (1.84–10.41)

0.001

Type-specific persistent infection

135

29

38.8 (22.4–51.7)

 Low-risk

78

7

12.4 (2.8–21.0)

Ref

Ref

 HPV-16

15

8

66.6 (20.5–85.9)

4.01 (1.45–11.10)

4.24 (1.49–12.10)

0.007

 HPV-18

5

1

20.0 (0.0–48.4)

2.04 (0.25–16.62)

2.25 (0.27–18.44)

0.451

 HPV-31

2

0

NA

NA

NA

NA

 HPV-33

5

3

70.0 (0.0–93.7)

5.95 (1.53–23.09)

4.56 (1.165–18.04)

0.030

 HPV-45

1

0

NA

NA

NA

NA

 HPV-52

12

2

9.1 (0.0–24.6)

1.49 (0.31–7.18)

1.81 (0.37–8.91)

0.464

 HPV-58

20

9

50.3 (17.0–70.3)

4.23 (1.58–11.37)

4.18 (1.54–11.33)

0.005